This analysis reviews the history and current status of biosimilar regulation in the US, concluding that changing the FDA’s interchangeability standards—as proposed by some policy makers—is a ...
Ooops... Something went wrong while loading this page.
Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM; Nasdaq: PHAR) today announced that 12 abstracts have been ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback